DRA contract ends & New advisory board member

Panion Animal Health AB’s Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.
Niels-Erik Manniche’s contract expires on the 31.st of March 2018, and he is available for the company in this period, if needed. Niels-Erik has been involved since the establishment of Panion and wishes us the best of luck for the future.

Anja Holm, CEO, takes over his responsibilities until the board has taken a new organizational decision.

Panion’s advisory board has been expanded with Dr. Curtis W. Dewey from Cornell University, New York.
Dr. Curtis Dewey, DVM, MS, is a Diplomate of the American College of Veterinary Internal Medicine (Neurolo-gy), a Diplomate of the American College of Veterinary Surgeons, and an Associate Professor at the Section of Neurology/Neurosurgery in the veterinary faculty of Cornell University, Ithaca, New York, U.S.A.

Dr. Dewey’s main research interests include seizure management, congenital disorders of the central nervous system, and complementary therapies for neurologic disease. Species focus is on dogs and cats.

Advisory board membership is a voluntary, independent, and non-remunerated position.

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.

Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.